RGC Regencell Bioscience Ltd: שווי פעילות לרווח לפני ריבית, מסים ופחת

Regencell Bioscience is establishing scientific authority by integrating Chinese medicine methods into the fight against cognitive decline. The EV/EBITDA ratio, accounting for capital structure, visualizes this trend, where the current value is 0.00. Fundamentals are bolstered by partnerships with clinics for formula testing and the leadership of Yat-Gaya Au, who is guiding the team through the early stage of commercial market penetration.

The EV/EBITDA multiple assesses the total enterprise value, including debt, relative to operating profit, allowing for the determination of the capital payback period excluding tax effects. The historical EV/EBITDA trend for Regencell Bioscience (RGC) on GURU.Markets, with a current value of 0.00, reflects the efficiency of the capital-intensive investments made by Regencell Bioscience (RGC) into ethical raw materials and ESG standards for neurological drug development, where stable operating cash flow is critical for servicing obligations.